Viral Respiratory Pathogens and Lung Injury

Clin Microbiol Rev. 2021 Mar 31;34(3):e00103-20. doi: 10.1128/CMR.00103-20. Print 2021 Jun 16.

Abstract

Several viruses target the human respiratory tract, causing different clinical manifestations spanning from mild upper airway involvement to life-threatening acute respiratory distress syndrome (ARDS). As dramatically evident in the ongoing SARS-CoV-2 pandemic, the clinical picture is not always easily predictable due to the combined effect of direct viral and indirect patient-specific immune-mediated damage. In this review, we discuss the main RNA (orthomyxoviruses, paramyxoviruses, and coronaviruses) and DNA (adenoviruses, herpesviruses, and bocaviruses) viruses with respiratory tropism and their mechanisms of direct and indirect cell damage. We analyze the thin line existing between a protective immune response, capable of limiting viral replication, and an unbalanced, dysregulated immune activation often leading to the most severe complication. Our comprehension of the molecular mechanisms involved is increasing and this should pave the way for the development and clinical use of new tailored immune-based antiviral strategies.

Keywords: COVID-19; SARS-CoV-2; respiratory tract; viral infections.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / therapeutic use
  • COVID-19
  • Child
  • Child, Preschool
  • DNA Viruses*
  • Female
  • Humans
  • Immunologic Factors / therapeutic use
  • Infant
  • Infant, Newborn
  • Interferons / therapeutic use
  • Lung / immunology
  • Lung / virology
  • Lung Injury* / diagnosis
  • Lung Injury* / drug therapy
  • Lung Injury* / immunology
  • Lung Injury* / virology
  • Male
  • Middle Aged
  • Pandemics
  • RNA Viruses*
  • Respiratory Tract Infections*
  • SARS-CoV-2
  • Virus Diseases*

Substances

  • Antiviral Agents
  • Immunologic Factors
  • Interferons